Mettler-Toledo International (MTD) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
30 Jul, 2026Executive summary
Q2 2026 reported sales increased 4% year-over-year to $1.027 billion, with local currency sales up 6% excluding a one-time tariff refund to customers.
Adjusted EPS for Q2 2026 was $11.46, a 14% increase year-over-year; reported EPS was $11.55, up from $9.76.
Strong organic sales growth, especially in China and emerging markets, contributed to performance.
Six-month reported sales increased 6% year-over-year to $1.974 billion; adjusted EPS for the period was $20.35, up 11%.
Strategic initiatives in sales, marketing, and productivity contributed to financial outperformance.
Financial highlights
Q2 2026 net sales reached $1,027M, up 4% year-over-year; adjusted gross profit rose 8% to $626M.
Adjusted gross margin improved by 30bp to 59.3%; adjusted operating profit up 9% to $309M.
Q2 2026 earnings before taxes were $289.4 million, up from $248.7 million in Q2 2025.
Gross margin for Q2 2026 was 63.3%, up from 59.0% in Q2 2025.
Adjusted free cash flow for Q2 2026 was $247.0 million; for the six months, $366.7 million.
Outlook and guidance
Management expects local currency sales to grow ~4% in Q3 2026; adjusted EPS forecasted at $12.00–$12.15, up 8–9%.
Full-year 2026 local currency sales growth expected at 4–5% (excluding tariff refunds); adjusted EPS guidance raised to $47.15–$47.50, up 10–11%.
Continued focus on leveraging automation, digitalization, and onshoring trends to drive growth.
Management remains agile in capturing new opportunities and executing strategic initiatives.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026